KR20100063672A - 에이취엠지-코에이 환원효소 억제제를 함유하는 안정한 약제학적 조성물 - Google Patents
에이취엠지-코에이 환원효소 억제제를 함유하는 안정한 약제학적 조성물 Download PDFInfo
- Publication number
- KR20100063672A KR20100063672A KR1020090119006A KR20090119006A KR20100063672A KR 20100063672 A KR20100063672 A KR 20100063672A KR 1020090119006 A KR1020090119006 A KR 1020090119006A KR 20090119006 A KR20090119006 A KR 20090119006A KR 20100063672 A KR20100063672 A KR 20100063672A
- Authority
- KR
- South Korea
- Prior art keywords
- coa reductase
- hmg
- lactone
- reductase inhibitor
- pharmaceutical composition
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
- 안정화제로서 글리세로인산마그네슘을 포함하는 안정한 비락톤형 HMG-CoA 환원효소 억제제 함유 약제학적 조성물.
- 제 1 항에 있어서, 비락톤형 HMG-CoA 환원효소 억제제는 로수바스타틴 또는 이의 약학적 허용가능한 염인 것을 특징으로 하는 비락톤형 HMG-CoA 환원효소 억제제 함유 약제학적 조성물.
- 제 1 항에 있어서, 상기 약제학적 조성물은 고지혈증, 고콜레스테롤혈증 또는 죽상동맥경화증의 치료 또는 예방용인 것을 특징으로 하는 비락톤형 HMG-CoA 환원효소 억제제 함유 약제학적 조성물.
- 안정화제로서 글리세로인산마그네슘을 사용하는 것을 특징으로 하는 비락톤형 HMG-CoA 환원효소 억제제 함유 제제의 안정화 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080122160 | 2008-12-03 | ||
KR20080122160 | 2008-12-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100063672A true KR20100063672A (ko) | 2010-06-11 |
KR101098597B1 KR101098597B1 (ko) | 2011-12-23 |
Family
ID=42363574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090119006A KR101098597B1 (ko) | 2008-12-03 | 2009-12-03 | 에이취엠지-코에이 환원효소 억제제를 함유하는 안정한 약제학적 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101098597B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012015168A2 (ko) * | 2010-07-28 | 2012-02-02 | 씨제이제일제당 (주) | 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7078399B2 (en) | 2001-12-13 | 2006-07-18 | Activbiotics, Inc. | Sulfhydryl rifamycins and uses thereof |
-
2009
- 2009-12-03 KR KR1020090119006A patent/KR101098597B1/ko active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012015168A2 (ko) * | 2010-07-28 | 2012-02-02 | 씨제이제일제당 (주) | 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 |
WO2012015168A3 (ko) * | 2010-07-28 | 2012-04-19 | 씨제이제일제당 (주) | 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR101098597B1 (ko) | 2011-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070202159A1 (en) | Pharmaceutical composition comprising stabilized statin particles | |
CA2692862C (en) | Stable compositions | |
US9399064B2 (en) | Pitavastatin-containing preparation and method for producing same | |
EP1978956A1 (en) | Complex formulation comprising amlodipine camsylate and simvastatin and method for preparation thereof | |
EP2566465A2 (en) | Stable rosuvastatin formulations | |
EP2233133B1 (en) | Stable Rosuvastatin Compositions | |
WO2006006021A2 (en) | Stabilized pharmaceutical compositions of preferably a statin | |
CA2621134C (en) | Pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof | |
KR101098597B1 (ko) | 에이취엠지-코에이 환원효소 억제제를 함유하는 안정한 약제학적 조성물 | |
CA2730665C (en) | Dosage form containing a statin | |
WO2003055467A1 (en) | Simvastatin dosage forms | |
EP1810667A1 (en) | Pharmaceutical composition comprising amorphous atorvastatin | |
WO2010030201A2 (en) | Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid | |
US20100178341A1 (en) | BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR | |
WO2008082124A1 (en) | Stabilized pharmaceutical drug of atorvastatin | |
US20120165386A1 (en) | Stable oral pharmaceutial composition of atorvastatin | |
AU2007355452B2 (en) | Improved pharmaceutical formulation containing an HMG-CoA reductase inhibitor and method for the preparation thereof | |
WO2010140992A1 (en) | Stable pharmaceutical compositions containing rosuvastatin calcium | |
RU2547574C2 (ru) | Лекарственная форма гиполипидемического действия и способ ее изготовления | |
JP6481453B2 (ja) | 経口固形製剤 | |
WO2008117154A2 (en) | Stable pharmaceutical compositions of hmg-coa reductase inhibitor and process for preparation thereof | |
WO2009091346A2 (en) | Stable pharmaceutical formulation and preparation methods | |
US20190070167A1 (en) | Pitavastatin containing preparation and method for producing same | |
RO129060B1 (ro) | Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă | |
EP1911441A2 (en) | Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131226 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141211 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161222 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171219 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181217 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20191127 Year of fee payment: 10 |